Key facts
- Notable investors include Chengdu High-Tech Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Mituo Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Mituo Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mituo Pharmaceutical
Manufacturer of mitochondrial-targeted pharmaceuticals intended for biomedical research institutions, pharmaceutical companies, and healthcare providers. The company is engaged in the research and development of mitochondrial caseinase P agonists and related medical compounds, thereby enabling clients to gain access to specialized therapies that improve cellular energy regulation and address complex diseases.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2024
- Website
- mitorpharm.com/
- Ownership
- Privately Held (backing)
Mituo Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mituo Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mituo Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.